Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$22.85 -2.2%	$20.64	$14.40 ▼ $47.00	$1.55B	1.13	963,293 shs	964,101 shs
DVAX Dynavax Technologies	$10.44 -2.8%	$10.04	$9.22 ▼ $14.63	$1.29B	1.03	2.15 million shs	1.51 million shs
EBS Emergent Biosolutions	$6.94 -5.0%	$6.48	$4.02 ▼ $15.10	$396.23M	2.09	1.68 million shs	895,631 shs
JNJ Johnson & Johnson	$155.38 -0.9%	$153.80	$140.68 ▼ $169.99	$377.32B	0.41	8.09 million shs	6.86 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	-2.18%	+7.13%	+7.48%	+28.37%	-42.23%
DVAX Dynavax Technologies	-2.79%	-1.42%	+1.66%	-1.97%	-1.14%
EBS Emergent Biosolutions	-4.68%	+0.84%	+10.74%	+50.83%	-38.68%
JNJ Johnson & Johnson	-0.98%	-0.24%	-0.97%	+0.93%	+4.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLDX Celldex Therapeutics	2.4737 of 5 stars	4.4	1.0	0.0	0.0	3.8	0.0	0.0
DVAX Dynavax Technologies	4.4421 of 5 stars	3.3	2.0	0.0	4.7	2.9	1.7	1.9
EBS Emergent Biosolutions	4.1111 of 5 stars	3.5	1.0	0.0	4.6	1.4	2.5	1.3
JNJ Johnson & Johnson	4.9392 of 5 stars	3.3	4.0	4.2	3.9	3.5	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDX Celldex Therapeutics	2.89	Moderate Buy	$50.11	119.30% Upside
DVAX Dynavax Technologies	2.50	Moderate Buy	$24.00	129.89% Upside
EBS Emergent Biosolutions	3.00	Buy	$14.33	106.59% Upside
JNJ Johnson & Johnson	2.55	Moderate Buy	$171.00	10.05% Upside

Current Analyst Ratings Breakdown

Latest EBS, JNJ, CLDX, and DVAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	JNJ Johnson & Johnson	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underperform ➝ Underperform
7/10/2025	JNJ Johnson & Johnson	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$169.00 ➝ $171.00
6/13/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
6/5/2025	JNJ Johnson & Johnson	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$181.00
5/13/2025	JNJ Johnson & Johnson	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/13/2025	JNJ Johnson & Johnson	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$169.00 ➝ $153.00
5/9/2025	CLDX Celldex Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $38.00
5/9/2025	CLDX Celldex Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$36.00 ➝ $31.00
5/9/2025	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$46.00 ➝ $43.00
5/7/2025	DVAX Dynavax Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$33.00 ➝ $31.00
5/6/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDX Celldex Therapeutics	$7.02M	216.07	N/A	N/A	$11.26 per share	2.03
DVAX Dynavax Technologies	$277.25M	4.52	$0.15 per share	67.82	$4.54 per share	2.30
EBS Emergent Biosolutions	$1.04B	0.36	$1.83 per share	3.80	$8.91 per share	0.78
JNJ Johnson & Johnson	$88.82B	4.21	$13.00 per share	11.95	$29.69 per share	5.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDX Celldex Therapeutics	-$157.86M	-$2.70	N/A	N/A	N/A	-2,366.07%	-23.46%	-22.35%	8/6/2025 (Estimated)
DVAX Dynavax Technologies	$27.31M	-$0.52	N/A	21.31	N/A	-20.39%	3.59%	2.20%	8/5/2025 (Estimated)
EBS Emergent Biosolutions	-$190.60M	-$2.71	N/A	3.35	N/A	-13.63%	-0.52%	-0.17%	8/5/2025 (Estimated)
JNJ Johnson & Johnson	$14.07B	$8.99	17.28	14.04	2.14	24.42%	33.46%	13.30%	7/16/2025 (Estimated)

Latest EBS, JNJ, CLDX, and DVAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	DVAX Dynavax Technologies	$0.12	N/A	N/A	N/A	$87.55 million	N/A
8/5/2025	Q2 2025	EBS Emergent Biosolutions	$0.21	N/A	N/A	N/A	$148.55 million	N/A
7/16/2025	Q2 2025	JNJ Johnson & Johnson	$2.65	N/A	N/A	N/A	$22.85 billion	N/A
5/8/2025	Q1 2025	CLDX Celldex Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	$1.08 million	$0.70 million
5/7/2025	Q1 2025	EBS Emergent Biosolutions	$0.49	$0.71	+$0.22	$1.19	$218.50 million	$222.20 million
5/6/2025	Q1 2025	DVAX Dynavax Technologies	$0.03	-$0.11	-$0.14	-$0.77	$70.01 million	$68.16 million
4/15/2025	Q1 2025	JNJ Johnson & Johnson	$2.59	$2.77	+$0.18	$4.54	$21.65 billion	$21.89 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
DVAX Dynavax Technologies	N/A	N/A	N/A	N/A	N/A
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$5.20	3.35%	N/A	57.84%	64 Years

Latest EBS, JNJ, CLDX, and DVAX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/15/2025	JNJ Johnson & Johnson	quarterly	$1.30	3.37%	5/27/2025	5/27/2025	6/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDX Celldex Therapeutics	N/A	21.67	21.67
DVAX Dynavax Technologies	0.49	11.93	10.84
EBS Emergent Biosolutions	1.20	6.32	3.51
JNJ Johnson & Johnson	0.49	1.26	1.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDX Celldex Therapeutics	N/A
DVAX Dynavax Technologies	96.96%
EBS Emergent Biosolutions	78.40%
JNJ Johnson & Johnson	69.55%

Insider Ownership

Company	Insider Ownership
CLDX Celldex Therapeutics	4.40%
DVAX Dynavax Technologies	2.98%
EBS Emergent Biosolutions	3.20%
JNJ Johnson & Johnson	0.16%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDX Celldex Therapeutics	150	66.38 million	63.46 million	Optionable
DVAX Dynavax Technologies	350	120.08 million	116.50 million	Optionable
EBS Emergent Biosolutions	2,420	54.28 million	52.54 million	Optionable
JNJ Johnson & Johnson	138,100	2.41 billion	2.40 billion	Optionable

EBS, JNJ, CLDX, and DVAX Headlines

Recent News About These Companies

Jim Cramer Notes Johnson & Johnson Talc Lawsuits “Puts a Damper on the Stock”

1 hour ago | insidermonkey.com

Johnson & Johnson Q2 Preview: Focus on tariff threat, MedTech softness

July 15 at 2:50 PM | seekingalpha.com

What's Next: Johnson & Johnson's Earnings Preview

July 15 at 2:20 PM | benzinga.com

Wolfe Research Affirms Outperform Rating on Johnson & Johnson (JNJ) on Improving Fundamentals

July 15 at 2:20 PM | msn.com

Should You Buy Johnson & Johnson Stock Before July 16?

July 15 at 2:20 PM | msn.com

Johnson & Johnson Medtech bags USFDA approval for updated Varipulse Platform Irrigation Rate

July 15 at 9:19 AM | medicaldialogues.inM

Massachusetts Financial Services Co. MA Has $3.03 Billion Position in Johnson & Johnson (NYSE:JNJ)

July 15 at 6:39 AM | marketbeat.com

Strata Wealth Advisors LLC Buys 1,827 Shares of Johnson & Johnson (NYSE:JNJ)

July 15 at 6:39 AM | marketbeat.com

Dakota Wealth Management Sells 5,563 Shares of Johnson & Johnson (NYSE:JNJ)

July 15 at 6:37 AM | marketbeat.com

Johnson & Johnson (NYSE:JNJ) Shares Bought by OVERSEA CHINESE BANKING Corp Ltd

July 15 at 6:25 AM | marketbeat.com

Lokken Investment Group LLC Decreases Stock Holdings in Johnson & Johnson (NYSE:JNJ)

July 15 at 6:20 AM | marketbeat.com

Apollon Wealth Management LLC Buys 5,572 Shares of Johnson & Johnson (NYSE:JNJ)

July 15 at 6:18 AM | marketbeat.com

Johnson & Johnson (NYSE:JNJ) Shares Acquired by Hohimer Wealth Management LLC

July 15 at 6:15 AM | marketbeat.com

Bogart Wealth LLC Cuts Stock Position in Johnson & Johnson (NYSE:JNJ)

July 15 at 6:04 AM | marketbeat.com

Johnson & Johnson (NYSE:JNJ) Shares Acquired by Signaturefd LLC

July 15 at 5:58 AM | marketbeat.com

Edgestream Partners L.P. Has $14.93 Million Stake in Johnson & Johnson (NYSE:JNJ)

July 15 at 5:52 AM | marketbeat.com

Focused Investors LLC Cuts Stock Position in Johnson & Johnson (NYSE:JNJ)

July 15 at 5:51 AM | marketbeat.com

Johnson & Johnson (NYSE:JNJ) Shares Purchased by Bleakley Financial Group LLC

July 15 at 5:42 AM | marketbeat.com

Securian Asset Management Inc. Sells 1,903 Shares of Johnson & Johnson (NYSE:JNJ)

July 15 at 5:42 AM | marketbeat.com

Should You Buy Johnson & Johnson Stock Before July 16th?

July 15 at 4:06 AM | fool.com

Johnson & Johnson MedTech gets updated FDA nod for Varipulse PFA

July 14 at 7:28 PM | massdevice.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EBS, JNJ, CLDX, and DVAX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

$22.85 -0.51 (-2.18%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$22.86 +0.01 (+0.07%)

As of 07/15/2025 05:22 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Dynavax Technologies NASDAQ:DVAX

$10.44 -0.30 (-2.79%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$10.44 0.00 (-0.05%)

As of 07/15/2025 04:24 PM Eastern

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Emergent Biosolutions NYSE:EBS

$6.94 -0.36 (-4.96%)

Closing price 07/15/2025 03:59 PM Eastern

Extended Trading

$7.24 +0.30 (+4.37%)

As of 07/15/2025 07:50 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Johnson & Johnson NYSE:JNJ

$155.38 -1.44 (-0.92%)

Closing price 07/15/2025 03:59 PM Eastern

Extended Trading

$155.98 +0.59 (+0.38%)

As of 07/15/2025 07:59 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time